Rating

Goldman Sachs Maintains Their Hold Rating on Deutsche Bank AG (DB)

Goldman Sachs analyst Jernej Omahen maintained a Hold rating on Deutsche Bank AG (DB) today and set a price target of $8.40. The company’s shares opened today at $7.59, close to its 52-week low of $6.61. According to TipRanks.com, Omahen is ranked #1943 out of 5229 analysts. Currently, the analyst consensus on Deutsche Bank AG […]

5
Like
Save
Lundin Mining (LUN) Gets a Buy Rating from Scotiabank

The Materials sector company, Lundin Mining (LUN), has received a rating update from a Wall Street analyst yesterday. Analyst Orest Wowkodaw from Scotiabank reiterated a Buy rating, with a C$10 price target. According to TipRanks.com, Wowkodaw is a 5-star analyst with an average return of 19.2% and a 59.7% success rate. Wowkodaw covers the Basic […]

7
Like
Save
Incyte Corp (INCY) Gets a Buy Rating from J.P. Morgan

In a report released today, Cory Kasimov from J.P. Morgan maintained a Buy rating on Incyte Corp (INCY). The company’s shares opened today at $74.61. According to TipRanks.com, Kasimov is a 2-star analyst with an average return of 0.3% and a 40.5% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx […]

5
Like
Save
Inogen (INGN) Gets a Buy Rating from Needham

In a report released today, Michael Matson from Needham maintained a Buy rating on Inogen (INGN), with a price target of $191. The company’s shares opened today at $92.30, close to its 52-week low of $88.21. According to TipRanks.com, Matson is a 5-star analyst with an average return of 12.2% and a 66.8% success rate. […]

2
Like
Save
Cantor Fitzgerald Keeps a Buy Rating on Xencor Inc (XNCR)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Xencor Inc (XNCR) today and set a price target of $40. The company’s shares opened today at $32.50. Young commented: “. We reiterate our Overweight rating and $40 price target. We think Xencor’s collaboration and license agreement with Astellas (ALPMF, NC) marks another source of […]

5
Like
Save
Maxim Group Keeps Their Buy Rating on Moleculin Biotech (MBRX)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX), with a price target of $3. The company’s shares opened today at $1.27. McCarthy commented: “Following last month’s clearance to begin its European clinical trial of WP1220 (STAT3 inhibitor) in the topical treatment of cutaneous T-cell lymphoma […]

4
Like
Save